fbpx Yourgene Health plc - Home
previous arrow
next arrow
Slider

CE-IVD Certification renewal

Manchester, UK – 26 September 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that in preparation for a 2020 product launch and as a contingency for BREXIT, the Company has successfully transferred its quality accreditation process to a new Notified Body, BSI NL (Netherlands), allowing the Company to continue to sell its systems in the European Economic Area (EEA).

As part of this transfer, Yourgene has been issued with a renewed CE-IVD Certificate from BSI NL covering the design and manufacture of its IONA® test, having been successfully audited against the requirements of the European Union In Vitro Diagnostic Directive (98/79/EC). Under the new EC Certification the Company’s CE-IVD mark will be valid until 25 January 2021. The new Certificate also enables the Company to complete the appointment of an identified EU-based Authorised Representative, to protect against potential no-deal Brexit scenarios.

Lyn Rees, CEO of Yourgene, commented:

"The smooth and successful transfer to our new Notified Body in the Netherlands is a testament to the regulatory team at Yourgene and to the robust systems we have in place for quality assurance. The move to BSI NL is a key part of our Brexit contingency planning and also prepares us for the launch of our new Illumina-based version of the IONA® test from early next year.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 667 1053

This email address is being protected from spambots. You need JavaScript enabled to view it.

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie / Ludovico Lazzaretti

Tel: +44 (0)20 7213 0880

Stifel Nicolaus Europe Limited (Sole Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Lianne Cawthorne / Anna Dunphy

Tel: +44 (0)20 7933 8780 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Mob: 07980 541 893 / 07584 391 303 / 07876 741 001

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

  • 13 January 2021 - DPYD screening recommended in Belgium +

    Yourgene Health plc
    ("Yourgene" or the "Group" or the "Company")

    DPYD screening recommended in Belgium

    Manchester, UK – 13 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the research article published on 11 January 2021, in Acta Clinica Belgica, titled: ‘Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).’

    The research article endorses screening for Dihydropyrimidine Dehydrogenase (DPD) deficiency which can cause severe and sometimes lethal side

    Read More
  • 11 January 2021 - Clarigene® SARS-CoV-2 Product Update and Partnerships with CityDoc and ReCoVa-19 +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Clarigene® SARS-CoV-2 Product Update
    and Partnerships with CityDoc and ReCoVa-19

    Manchester, UK – 11 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following the Company’s statement on 24 December 2020, regarding the new virus strain (VUI-202012/01 SARS-CoV-2 variant), Yourgene’s wet lab testing is now complete and has confirmed that the performance of the Clarigene ® SARS-CoV-2 assay is not impacted by any currently

    Read More
  • 24 December 2020 - COVID-19 update: approved provider for UK Government and response to new virus strain +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    COVID-19 update: approved provider for UK Government and r esponse to new virus strain

    Manchester, UK – 24 December 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Genomic Services has been added to the UK Government’s approved COVID-19 private testing providers list for the Test to Release for International Travel scheme introduced on 15 December 2020 (“Test to Release”), and also for

    Read More
  • 17 December 2020 - Half-year Report +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Half-year Report

    Manchester, UK – 17 December 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half-year report for the six months ended 30 September 2020.

    The results demonstrate the resilience of the Group’s core business during the first few months of the global pandemic, its responsiveness in launching COVID-19 testing solutions rapidly and its

    Read More
  • 2 December 2020 - DPYD kits recommended by NHS England +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    DPYD kits recommended by NHS England

    Manchester, UK – 2 December 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the Clinical Commissioning Urgent Policy Statement, published by NHS England, titled: ‘Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies’ recommending the routine availability of DPYD testing prior to the start of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe side effects.

    Read More
  • 5 November 2020 - Directorate change +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Directorate change
    Chief Scientific Officer appointment to drive new product development roadmap

    Manchester, UK – 5 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the appointment of Dr. Joanne Mason as Chief Scientific Officer as a director of the Company with immediate effect.

    Dr Mason has been director of Research & Development (non-board position) at Yourgene since joining the Company in December 2019,

    Read More
  • 3 November 2020 - Partnership with Take2 Health Limited +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Partnership with Take2 Health Limited
    Yourgene to run genomic test for Nasopharyngeal Carcinoma (NPC) Screening in Taiwan

    Manchester, UK – 3 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its wholly-owned subsidiary, Yourgene Health Taipei, has signed a regional marketing and services agreement (the “Agreement”) with Hong Kong based Take2 Health Limited (“Take2”), to promote Take2’s clinically-validated genomic test for Nasopharyngeal Carcinoma

    Read More
  • 26 October 2020 - Half-year Trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Half-year Trading update
    H1 year-on-year growth demonstrating the resilience of the Company

    Manchester, UK – 26 October 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the half-year ended 30 September 2020 (“H1 2020”).

    Revenues for the half-year ended 30 September 2020 were £8.2m (H1 2019: £7.8m), up 5% compared to the previous year, with strong European revenues offsetting the

    Read More
  • 23 October 2020 - CQC registration +

    Yourgene Health plc
    (“Yourgene Health” or the "Company")

    CQC registration

    Manchester, UK – 23 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received notification from the Care Quality Commission (“CQC”) that the Company’s facilities at Citylabs 1.0 in Manchester are now a second registered location from which to perform diagnostics and screening procedures.

    The extension of the Company’s current CQC registration allows NIPT testing greater flexibility to operate

    Read More
  • 21 October 2020 - Yourgene Genomic Services collaboration with Cytox +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services collaboration with Cytox

    Partnership with Cytox to enable clinical access to genoSCORE™ - a new genetic test to determine the risk of developing Alzheimer’s disease

    Manchester, UK – 21 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces a new collaboration between the recently launched Yourgene Genomic Services (“YGS”) and Cytox Ltd (“Cytox”), for a beta-testing genomic study on their

    Read More
  • 12 October 2020 - Elucigene DPYD tests to be used routinely in Wales +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Elucigene DPYD tests to be used routinely in Wales

    Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapy
    DPYD tests screen patients to identify risk of severe side effects from certain chemotherapy treatments

    Manchester, UK – 12 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its oncology product, Elucigene DPYD test, is now being used in Wales to routinely

    Read More
  • 8 October 2020 - Strategic reproductive health partnership secured in Japan +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Strategic reproductive health partnership secured in Japan

    Manchester, UK – 8 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into a 5-year strategic partnership with a blue chip Japanese multinational to provide Yourgene’s Flex™ Analysis Software (“ Flex Software”) bioinformatics platform for a reproductive health project.

    Yourgene and the Japanese partner (the “Partner”) have entered into a technology transfer

    Read More
  • 7 October 2020 - IONA® Nx awarded contract with St George’s NHS Hospital +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    IONA ® Nx awarded contract with St George’s NHS Hospital

    Manchester, UK – 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the contract for non-invasive prenatal testing (NIPT) using its newly-launched IONA ® Nx NIPT Workflow ('IONA ® Nx'), by the prestigious St George’s NHS Trust Foundation in Tooting, South London (“St George’s”). The contract, subject to signing by both

    Read More
  • 28 September 2020 - Launch of Yourgene Genomic Services +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of Yourgene Genomic Services

    Manchester, UK – 28 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of Yourgene Genomic Services, an integration and expansion of the Company’s international service laboratory offerings. Yourgene Genomic Services becomes a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations.

    Yourgene Genomic Services (“YGS”) will bring together

    Read More
  • 24 September 2020 - DPD reimbursement in Germany +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    DPD reimbursement in Germany

    Manchester, UK – 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national reimbursement authority in Germany, has approved the reimbursement for testing of Dihydropyrimidine Dehydrogenase (DPD) deficiency in Germany, which opens up the clinical market in this region for the Company’s first oncology genotyping product, the Elucigene DPYD Test. The

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen